恩格列净改善肝酶或提示肝脏脂肪减少
该研究基于EMPA-REG OUTCOME®等三项随机试验数据,评估恩格列净对2型糖尿病患者转氨酶的影响。结果显示恩格列净较安慰剂或格列美脲显著降低ALT,降幅在基线ALT最高三分位者最大,AST降幅较小,模式与肝脏脂肪减少一致。
要点
- 恩格列净较安慰剂显著降低ALT,第28周校正均差-2.22 U/l。
- 基线ALT最高三分位者降幅最大,校正均差-4.36 U/l。
- ALT降低 largely 独立于体重和HbA1c变化,AST降幅较小。
核心结论
- 恩格列净可降低2型糖尿病患者的转氨酶,ALT降幅大于AST,该模式或与肝脏脂肪减少一致,尤其在ALT水平较高时。
研究设计与样本
- 基于EMPA-REG OUTCOME®试验(n=7020)、四项24周安慰剂对照试验汇总数据(n=2477)及一项恩格列净对比格列美脲104周试验(n=1545)的随机试验分析。
主要发现
- EMPA-REG OUTCOME®中第28周ALT自基线变化:恩格列净组-2.96±0.18 U/l vs 安慰剂组-0.73±0.25 U/l,校正均差-2.22 U/l(95%CI -2.83, -1.62;p<0.0001)。
- 基线ALT最高三分位者第28周安慰剂校正均差-4.36 U/l(95%CI -5.51, -3.21;p<0.0001)。
- 四项24周汇总数据第24周恩格列净 vs 安慰剂ALT变化校正均差-3.15 U/l(95%CI -4.11, -2.18)。
- 恩格列净 vs 格列美脲第28周ALT变化校正均差-4.88 U/l(95%CI -6.68, -3.09)。
- ALT降低 largely 独立于体重或HbA1c变化;AST变化模式类似但降幅 considerably 较低。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes. METHODS: Changes from baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed in the EMPA-REG OUTCOME® trial (n = 7020), pooled data from four 24-week placebo-controlled trials (n = 2477) and a trial of empagliflozin vs glimepiride over 104 weeks (n = 1545). Analyses were performed using data from all participants and by tertiles of baseline aminotransferases. RESULTS: In the EMPA-REG OUTCOME® trial, mean ± SE changes from baseline ALT at week 28 were -2.96 ± 0.18 and -0.73 ± 0.25 U/l with empagliflozin and placebo, respectively (adjusted mean difference: -2.22 [95% CI -2.83, -1.62]; p < 0.0001). Reductions in ALT were greatest in the highest ALT tertile (placebo-adjusted mean difference at week 28: -4.36 U/l [95% CI -5.51, -3.21]; p < 0.0001). The adjusted mean difference in change in ALT was -3.15 U/l (95% CI -4.11, -2.18) with empagliflozin vs placebo at week 24 in pooled 24-week data, and -4.88 U/l (95% CI -6.68, -3.09) with empagliflozin vs glimepiride at week 28. ALT reductions were largely independent of changes in weight or HbA1c. AST changes showed similar patterns to ALT, but the reductions were considerably lower. CONCLUSIONS/INTERPRETATION: These highly consistent results suggest that empagliflozin reduces aminotransferases in individuals with type 2 diabetes, in a pattern (reductions in ALT>AST) that is potentially consistent with a reduction in liver fat, especially when ALT levels are high.
引用
- Sattar N, Fitchett D, Hantel S, et al. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia. 2018. PMID: 30066148. doi:10.1007/s00125-018-4702-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。